PRDM9 and hepatocellular carcinoma: In HCC cell lines, 5-azacytidine and the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A (DZNep) enhance the efficacy of immunotherapy for HCC by the activation of transcriptionally repressed genes [52].